

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

NCT07142980

Status	RECRUITING
Phase	Phase 1
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (6)

- Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;
- Aged between 18-75 years old;
- ECOG performance status (PS) score of 0 or 1;
- Life expectancy \geq 3 months;
- At least one measurable lesion per RECIST v1.1;

... and 1 more (see full listing online)

Exclusion (11)

- Presence of central nervous system (CNS) metastases;
- Participants with gastrointestinal diseases that affect drug administration/absorption;
- Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;
- Presence of serious pulmonary diseases;
- Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;

... and 6 more (see full listing online)

Locations (1 total)

Fudan University Affiliated Cancer Hospital, Shanghai, Shanghai Municipality, China